Multiple sclerosis is autoimmune immunopathological and neurodegenerative disease which pathogenesis is described in deep detail. This is the background for therapeutical interventions which are able to modulate the natural history of multiple sclerosis positively. New drugs are now approved to be effective in the treatment of multiple sclerosis. However, classical drugs such as recombinant interferons β and glatiramer acetate still display the substantial therapeutical potential. These drugs not only positively modulate immunopathological inflammatory response. In addition, their effects on reparation of CNS tissues to prevent the development of neurodegeneration are evidenced now.